Growth Metrics

Eli Lilly (LLY) Gross Margin (2009 - 2026)

Eli Lilly posted quarterly Gross Margin of 81.93% for Q1 2026, down 59.0% year-on-year from 199.84% in Q1 2025, and down 0.71% on a QoQ basis from 82.52% in Q4 2025.

Eli Lilly (LLY) has 18 years of Gross Margin data on file, last reported at 81.93% in Q1 2026.

  • For the quarter ending Q1 2026, Gross Margin fell 59.0% year-over-year to 81.93%; the trailing twelve-month figure through Mar 2026 stood at 82.83% (up 113.0% YoY), and the FY2025 full-year result was 83.04%, up 173.0% from the prior year.
  • Gross Margin for Q1 2026 stood at 81.93%, down from 82.52% in the prior quarter.
  • Across five years, Gross Margin topped out at 84.27% in Q2 2025 and bottomed at 73.47% in Q1 2022.
  • The 5-year median for Gross Margin is 80.89% (2023), against an average of 80.16%.
  • Peak annual rise in Gross Margin reached 693 bps in 2022, while the deepest fall reached 162 bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 78.8% in 2022, then climbed by 3 bps to 80.89% in 2023, then advanced by 2 bps to 82.24% in 2024, then advanced by 0 bps to 82.52% in 2025, then slipped by 1 bps to 81.93% in 2026.
  • The last three Gross Margin figures came in at 81.93% (Q1 2026), 82.52% (Q4 2025), and 82.91% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 81.93%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 66.31%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 71.88%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 74.24%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 68.16%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 79.24%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -51.69%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 70.22%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 81.93%
Dec 31, 2025 82.52%
Sep 30, 2025 82.91%
Jun 30, 2025 84.27%
Mar 31, 2025 82.52%
Dec 31, 2024 82.24%
Sep 30, 2024 81.02%
Jun 30, 2024 80.80%
Mar 31, 2024 80.91%
Dec 31, 2023 80.89%
Sep 30, 2023 80.42%
Jun 30, 2023 78.26%
Mar 31, 2023 76.63%
Dec 31, 2022 78.80%
Sep 30, 2022 77.25%
Jun 30, 2022 77.95%
Mar 31, 2022 73.47%
Dec 31, 2021 74.37%
Sep 30, 2021 78.87%
Jun 30, 2021 71.02%
Mar 31, 2021 72.40%
Dec 31, 2020 76.88%
Sep 30, 2020 76.89%
Jun 30, 2020 77.78%
Mar 31, 2020 79.26%
Dec 31, 2019 79.02%
Sep 30, 2019 78.55%
Jun 30, 2019 80.04%
Mar 31, 2019 77.64%
Dec 31, 2018 79.96%
Sep 30, 2018 78.28%
Jun 30, 2018 77.90%
Mar 31, 2018 76.54%
Dec 31, 2017 73.30%
Sep 30, 2017 71.96%
Jun 30, 2017 73.01%
Mar 31, 2017 74.22%
Dec 31, 2016 74.55%
Sep 30, 2016 73.02%
Jun 30, 2016 72.89%
Mar 31, 2016 72.81%
Dec 31, 2015 74.16%
Sep 30, 2015 75.06%
Jun 30, 2015 75.53%
Mar 31, 2015 74.32%
Dec 31, 2014 75.53%
Sep 30, 2014 74.01%
Jun 30, 2014 75.90%
Mar 31, 2014 73.89%
Dec 31, 2013 76.13%
Sep 30, 2013 79.25%
Jun 30, 2013 80.35%
Mar 31, 2013 79.32%
Dec 31, 2012 79.05%
Sep 30, 2012 77.89%
Jun 30, 2012 79.53%
Mar 31, 2012 78.62%
Dec 31, 2011 78.14%
Sep 30, 2011 78.23%
Jun 30, 2011 80.36%
Mar 31, 2011 79.79%
Dec 31, 2010 80.08%
Sep 30, 2010 82.00%
Jun 30, 2010 81.68%
Mar 31, 2010 79.54%
Dec 31, 2009 75.88%
Sep 30, 2009 80.47%
Jun 30, 2009 82.10%
Mar 31, 2009 83.82%